Compare Incyte Corporation (INCY) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Monster Beverage Corp — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Monster Beverage Corp trades at $43.64 (market cap $85.51B). The key difference: Monster Beverage Corp is far larger — about 3.7× Incyte Corporation's market cap, and Monster Beverage Corp is more actively traded (8,569,709 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Monster Beverage Corp for 72 Days on average.
| INCY | MNST | |
|---|---|---|
Market Cap | $22.85B | $85.51B |
Volume | 1,927,029 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $49.97 |
52-Week Low | $83.80 | $33.16 |
Typical Hold Time | 33 Days | 72 Days |
Enterprise Value | $18.35B | $83.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Monster Beverage (MNST) trades at $43.65, up 1.8% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $0.30 exceeding expectations. Revenue growth accelerated to $8.29B in 2025 with impressive 23.08% net margins. Analyst consensus is bullish with 52% buy ratings and $98.22 price target, representing 125% upside potential. Recent 1:2 stock split on August 11, 2026, enhances accessibility while maintaining zero long-term debt.
MNST presents compelling growth prospects with international expansion driving 35% sales surge and clean balance sheet. However, elevated valuation multiples (P/E 40.42) and regulatory challenges in key markets like India pose risks. The stock's technical strength and fundamental momentum support continued upside, though investors should monitor margin pressures from inflation and competitive dynamics in the energy drink sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
